US Patent 8,323,671 Scope and Claims Analysis: breadth across anemia and wound-healing methods and the patent estate risk profile
US Patent 8,323,671 is a method-of-treatment patent that claims a large Markush-enabled chemical universe (core scaffold with variable aryl/heteroaryl substituents and side-chain features) for at least two therapeutic indications: anemia and wound healing. Claim 1 is the primary independent claim and is extremely broad at the formula level, while dependent claims narrow by selecting specific R substituent classes (phenyl, halo/alkoxy/cyano, heteroaryl) and by constraining linker and terminal moieties (R2, R3, L, R8a/R8b, and specific R10 substitution patterns). Claims 40–45 and their wound-healing counterparts provide a curated list of specific compound embodiments within the broader formula scope, increasing infringement leverage for named products in discovery and claim construction.
US Patent 8,323,671: What is the claimed invention and what do the claims cover?
Answer: The patent covers administering an “effective amount” of compounds having a defined general formula to treat anemia (Claims 1–39, and Claim 40) and to promote wound healing (Claims 41–47). The chemical scope is governed by a variable substituent set (R, R2, R3, linker unit L, and substitutions on a terminal heteroaryl/amide-like region), with dependent claims narrowing to specific phenyl/heteroaryl substituent sets and to specific functional groups such as hydroxy, methoxy, ethoxy, and amino dialkylamino variants.
Core structure variables (as read from Claim 1)
Claim 1 recites a compound class defined by a general formula with key definitional variables:
- R: substituted or unsubstituted phenyl or heteroaryl, with allowed substituents including:
- C1–C4 linear/branched/cyclic alkyl
- C1–C4 linear/branched/cyclic alkoxy
- C1–C4 haloalkyl
- halogen
- CN
- —NHC(O)R4
- —C(O)NR5aR5b
- additional heteroaryl
- fused-ring substitution option (fused ring with 5–7 atoms)
- R4: C1–C4 linear/branched/cyclic alkyl
- R5a and R5b: each H or C1–C4 alkyl, or taken together to form a 3–7 atom ring
- R2: —OR6 or —NR7aR7b, where R6 is H or C1–C4 alkyl; R7a/R7b are H or C1–C4 alkyl, or can form a 3–7 atom ring
- R3: H, methyl, or ethyl
- L: linker unit —[C(R8aR8b)]n— where R8a/R8b are H/methyl and n is 1–3
- R9: H or methyl
- Salt option: pharmaceutically acceptable salts
This is a broad Markush-style claim: the “treat anemia/wound healing” step is the function, while the chemical universe is the driver of scope.
What patents protect anemia treatments under US 8,323,671 and how broad are the Markush terms?
Answer: US 8,323,671 protects method-of-treatment claims for anemia by administering the claimed compound class. The breadth comes from Claim 1’s wide R substituent definitions and from the inclusion of both:
- phenotype-adjacent functional groups at R2 (hydroxy, alkoxy, and amino variants), and
- diverse aryl/heteroaryl electronics (halo, CN, alkoxy, alkyl, amide/urea-like motifs, and fused/heteroaromatic rings).
Claim architecture for anemia
- Independent claim: Claim 1 (general formula, treating anemia)
- Dependent narrowing: Claims 2–19 constrain R and sub-parameters (phenyl/heteroaryl selection, specific substituted phenyl lists, R2 substitutions, linker unit, R3 constraint, and R10 substitution patterns)
- Specific embodiment list: Claim 40 enumerates many specific compound structures (esters, amides, parent acids) that fall within the formula universe
Key breadth levers in the anemia set
- R substituent breadth (Claim 3–11): Explicitly lists:
- fluoro/chloro phenyl (2-,3-,4- positions)
- methoxy/ethoxy/iso-propoxy phenyl (2-,3-,4- positions)
- cyano phenyl (2-,3-,4- positions)
- carbamoyl-phenyl
- multiple heteroaryl classes (pyridyl, pyrimidyl, isoquinolinyl, thiazolyl, tetrazolyl/triazolyl/imidazolyl/furyl/thiophenyl)
- R2 functional-group breadth (Claims 12–15, plus later compound-specific Claims 21–24 etc.):
- —OH (via R2 = —OR6 with R6 = H)
- —OCH3, —OCH2CH3
- —NH2, —NHCH3, —N(CH3)2
- Linker flexibility (Claims 17–19):
- L = —CH2CH2— or —C(CH3)2—
- or L = —CH2—
- and separately in Claim 19, R8a/R8b can vary with R3 = H/methyl and R10 substitution patterns
- R10 substitution patterns (Claim 19 and downstream embodiments):
- fluoro, chloro, CF3, methyl
- fused ring option from two adjacent R10 units forming a 6-member ring with 1 or 2 oxygen atoms subject to non-adjacent oxygen rule
Practical implication for infringement mapping
For product-level clearance, Claim 40 provides a direct “named-compound list” that can be matched to:
- chemical identity
- salt form (if the product is a salt)
- prodrug/ester vs acid vs amide format (the list includes methyl esters, free acids, and amides)
This reduces the need to prove full formula alignment for many candidates.
What patents protect wound-healing promotion under US 8,323,671 and how does that scope compare to anemia?
Answer: The wound-healing coverage mirrors the anemia coverage through Claims 41–47: Claim 41 is the wound-healing analog of Claim 1 (same general formula definition and same substituent/functional-group latitude), while Claims 42–46 narrow similarly and Claim 47 enumerates specific compound embodiments.
Claim symmetry
- Independent anemia claim: Claim 1
- Independent wound-healing claim: Claim 41
- Dependent constraints: Claim 42 parallels Claim 19/20-type constraints for compound embodiments, and Claims 43–46 parallel Claim 21–24/29-type constraints (R2 and R8a/R8b conditions)
Specific compound list differences
Claims 40 (anemia) and 47 (wound healing) are largely overlapping in the enumerated chemistry set. Claim 47 is not merely a duplicate; it has different formatting and includes the same general functional-group patterns (esters/amides/free acids) and similar aryl/heteroaryl substitution choices. For validity and infringement, the overlap supports a narrative that the same scaffold is used for both therapeutic uses, which can complicate design-around strategies that target therapeutic indication.
What is the scope of the chemical formula in Claim 1: which substituents and linkers are allowed?
Answer: Claim 1 allows broad substitution at the aryl/heteroaryl position (R), broad substituent types on R2 (hydroxy/alkoxy and dialkylamino), limited variation in R3 (H/methyl/ethyl), and limited variation in the linker carbon substituents (R8a/R8b are H/methyl, and n ranges 1–3). R9 is H or methyl. R10 appears in Claim 19 and downstream claim sets, controlling additional terminal substitution on a further aromatic-like region.
Parameter-by-parameter scope
- R (aryl/heteroaryl): phenyl/heteroaryl with allowed substituents including halogens, alkoxy, alkyl, haloalkyl, CN, and intramolecularly relevant amide/amide-like motifs (—NHC(O)R4 and —C(O)NR5aR5b), plus heteroaryl substituents and fused-ring options.
- R2 (substitution at the main scaffold):
- —OR6 where R6 is H or C1–C4 alkyl
- —NR7aR7b where R7a/R7b are H or C1–C4 alkyl or form a 3–7 atom ring
- R3: H/methyl/ethyl
- L (linker): —[C(R8aR8b)]n— with:
- R8a and R8b each H/methyl
- n = 1–3
- R9: H/methyl
- Salt: allowed for all compounds described
Which specific compounds are enumerated in the independent claim sets (Claims 40 and 47)?
Answer: Claims 40 and 47 list multiple specific chemical embodiments. They include chlorophenyl and fluoro/alkyl/cyano substitutions, heteroaryl-containing analogs, and multiple functional-group formats including methyl esters, free acids, and amides.
Enumerated compounds under anemia (Claim 40)
The Claim 40 list includes, among others:
- methyl ester compounds with varied chloro-/fluoro-/methyl/ethyl/trifluoromethyl/cyano substituents on the phenyl ring combined with a 3-hydroxypyridine-2-carbonyl motif
- compounds with additional amide/heterocycle substituents such as:
- carbamoyl-phenyl
- pyrrolidine-1-carbonyl
- cyclopropanecarbonyl
- 2H-tetrazol-5-yl
- bipyridinyl carbonyl motifs
- pyrimidinyl, isoquinolinyl, thiazolyl substituents
- non-ester forms:
- amino-acetic acid derivatives (shown as “amino}-acetic acid”)
- amide forms with N-(2-amino-2-oxo-…) variants
- salt forms are explicitly covered
Enumerated compounds under wound healing (Claim 47)
The Claim 47 list includes the same family:
- methyl ester variants
- amino-acetic acid variants
- amide variants with 2-amino-2-oxoethyl / 1,1-dimethylethyl / 1-methyl-… structural features
- the same broad pattern of aryl substitution (chloro, fluoro, methyl, ethyl, isopropyl, CF3, cyano, carbamoyl)
How do dependent claims narrow the “R” substituent set and what does that mean for design-around?
Answer: Dependent claims create multiple “gateways” into infringement analysis. Even if a candidate compound is not identical to an enumerated example in Claim 40/47, it can still fall within Claim 1 if it fits the Markush definitions. Conversely, if a candidate is close to an enumerated example, dependent claims provide clearer claim-construction hooks.
Dependent claim narrowing for R
- Phenyl constraints (Claims 2–4):
- Claim 2: R is substituted/unsubstituted phenyl
- Claim 3: specific fluoro/chloro positional phenyl options
- Claim 4: specific methoxy/ethoxy/iso-propoxy phenyl options and cyano phenyl options
- Heteroaryl constraints (Claims 8–11):
- Claim 8: enumerates particular heteroaryl unit choices (tetrazolyl, triazolyl, imidazolyl, furyl, thiophenyl)
- Claim 10: pyridinyl, pyrimidinyl, isoquinolinyl (selected positions)
- Claim 11: thiazolyl plus overlap with tetrazolyl/triazolyl/imidazolyl/furan/thiophene options
Dependent claim narrowing for R2
- Claim 12: R2 = —OH
- Claim 13: R2 = —OCH3
- Claim 15: R2 in {—NH2, —NHCH3, —N(CH3)2}
Dependent claim narrowing for linker and carbon substitution
- Claim 17: L is —CH2CH2— or —C(CH3)2—
- Claim 18: L is —CH2—
- Claim 24 (and similar in the later compound constraint set): R8a and R8b are both hydrogen
What is the risk of “treat anemia” vs “treat wound healing” claim overlap in enforcement?
Answer: Claim 1 and Claim 41 cover the same general compound class but apply to different treatment outcomes. For enforcement and licensing strategy, that creates two independent infringement theories:
- administering the compound for anemia
- administering the compound for wound healing
A candidate product with the same active compound could be implicated in either therapeutic use depending on labeling, prescribing patterns, clinical study indications, and marketing.
How strong is the patent estate around US 8,323,671 based on claim breadth (intra-patent strength proxies)?
Answer: Strength proxies from the claim set suggest high coverage breadth inside the patent itself:
- Very broad Markush chemical scope in Claim 1
- Multiple explicit dependent narrowing routes into specific aryl/heteroaryl sets
- Multiple explicit compound embodiment lists in Claims 40 and 47
- Therapeutic indication diversity (anemia and wound healing), reducing the chance that a design-around can avoid all method uses
This is a strong enforcement posture for compound-format variants (ester vs acid vs amide) that still fit the same scaffold and substituent definitions.
What generic entry risks exist for products that fall within the enumerated compound list?
Answer: If an ANDA/505(b)(2) or non-authorization pathway seeks to market a drug containing a compound within Claim 40/47, the risk concentrates on method-of-use claims. Even if the generic’s label is carved away, Paragraph IV-style arguments can still fail if product use in the real world or in clinical settings maps to the method claims.
From a practical lens, the enumerated lists in Claims 40 and 47 are the most direct infringement anchors.
How to interpret “pharmaceutically acceptable salt” coverage in Claims 1 and 40/41/47 for freedom-to-operate
Answer: The claim text expressly covers salts. That means:
- changing from a free base/free acid to a pharmaceutically acceptable salt does not avoid Claim 1/41 if the core compound is the same
- however, a salt that changes the chemical identity beyond “salt” status (for example, a prodrug, cocrystal, or materially different chemical structure) would require separate mapping to Claim 1’s compound formula, not just salt conversion
Which parts of the claim are most likely to drive claim construction disputes?
Answer: Likely hotspots are:
- defining boundaries of the substituent variables (R and R10, especially fused-ring substitution constraints)
- interpretation of linker unit L and n range (1–3) in Claim 1
- whether specific ring-forming options for R5a/R5b and R7a/R7b match the candidate’s exact heterocycle geometry and atom counts
- the scope of “effective amount” is usually not a major novelty point for claim construction, but it is an enforcement element for method infringement
The dependent claim lists reduce ambiguity for enumerated compounds but do not eliminate interpretive disputes for “between” structures that fall only under Markush breadth.
Key Takeaways
- US Patent 8,323,671 is a method-of-treatment patent with extremely broad Markush chemical coverage in Claim 1 and Claim 41 for two indications: anemia and wound healing.
- Claim breadth is driven by flexible R aryl/heteroaryl substitution, functional-group variation at R2 (hydroxy/alkoxy and primary/secondary/tertiary amine options), and controlled linker variability (L with n = 1–3 and R8a/R8b in H/methyl).
- Claims 40 and 47 enumerate many specific compound embodiments, providing strong practical infringement anchors for compound-level clearance.
- Therapeutic overlap creates enforcement optionality: the same compound family can be pursued under different method-of-use theories depending on labeling and real-world use.
FAQs
1) Does US 8,323,671 cover salts of the claimed compounds?
Yes. Claim 1 and Claim 40/41/47 explicitly include “pharmaceutically acceptable salts.”
2) Can a compound avoid infringement by changing ester vs acid vs amide format?
Only if the changed structure falls outside Claim 1’s defined chemical formula scope. The enumerated sets in Claims 40 and 47 include multiple formats, signaling that format changes can still be inside the claim universe.
3) Are there explicit compound examples in the patent beyond the Markush formula?
Yes. Claims 40 and 47 list numerous specific compounds (including methyl esters, acids, and amides) that sit within the broader formula coverage.
4) Are anemia and wound healing both claimed under US 8,323,671?
Yes. Anemia is covered under Claim 1 and related dependent claims (and Claim 40), while wound healing is covered under Claim 41 and related dependent claims (and Claim 47).
5) What dependent claim features most affect whether a candidate compound falls within coverage?
R substituent class (phenyl vs heteroaryl and specific aryl lists), R2 functional group (—OH, —OCH3, —OCH2CH3, and dialkylamino variants), and linker L and carbon substitution constraints (L = —CH2— or —CH2CH2— or —C(CH3)2— and R8a/R8b constraints).
References
- United States Patent No. 8,323,671.
